Literature DB >> 15153483

Extensive replicative capacity of human central memory T cells.

Marcela V Maus1, Birgit Kovacs, William W Kwok, Gerald T Nepom, Katia Schlienger, James L Riley, David Allman, Terri H Finkel, Carl H June.   

Abstract

To characterize the replicative capacity of human central memory (T(CM)) CD4 T cells, we have developed a defined culture system optimized for the ex vivo expansion of Ag-specific CD4(+) T cells. Artificial APCs (aAPCs) consisting of magnetic beads coated with Abs to HLA class II and a costimulatory Ab to CD28 were prepared; peptide-charged HLA class II tetramers were then loaded on the beads to provide Ag specificity. Influenza-specific DR*0401 CD4 T(CM) were isolated from the peripheral blood of normal donors by flow cytometry. Peptide-loaded aAPC were not sufficient to induce resting CD4 T(CM) to proliferate. In contrast, we found that the beads efficiently promoted the growth of previously activated CD4 T(CM) cells, yielding cultures with >80% Ag-specific CD4 cells after two stimulations. Further stimulation with peptide-loaded aAPC increased purity to >99% Ag-specific T cells. After in vitro culture for 3-12 wk, the flu-specific CD4 T(CM) had surface markers that were generally consistent with an effector phenotype described for CD8 T cells, except for the maintenance of CD28 expression. The T(CM) were capable of 20-40 mean population doublings in vitro, and the expanded cells produced IFN-gamma, IL-2, and TNF-alpha in response to Ag, and a subset of cells also secreted IL-4 with PMA/ionomycin treatment. In conclusion, aAPCs expand T(CM) that have extensive replicative capacity, and have potential applications in adoptive immunotherapy as well as for studying the biology of human MHC class II-restricted T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153483     DOI: 10.4049/jimmunol.172.11.6675

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Adoptive immunotherapy: good habits instilled at youth have long-term benefits.

Authors:  Chrystal M Paulos; Megan M Suhoski; Gabriela Plesa; Tianying Jiang; Samik Basu; Tatiana N Golovina; Shuguang Jiang; Nicole A Aqui; Daniel J Powell; Bruce L Levine; Richard G Carroll; James L Riley; Carl H June
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 2.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

3.  Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.

Authors:  Mark P Rubinstein; Colleen A Cloud; Tracy E Garrett; Caitlin J Moore; Kristina M Schwartz; C Bryce Johnson; David H Craig; Mohamed L Salem; Chrystal M Paulos; David J Cole
Journal:  J Am Coll Surg       Date:  2012-02-22       Impact factor: 6.113

4.  Interleukin-7 signalling is sufficient to phenotypically and functionally prime human CD4 naive T cells.

Authors:  Elizabeth Z Managlia; Alan Landay; Lena Al-Harthi
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

5.  Toward synthetic biology with engineered T cells: a long journey just begun.

Authors:  Carl H June
Journal:  Hum Gene Ther       Date:  2014-09       Impact factor: 5.695

Review 6.  Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street.

Authors:  David M Barrett; Stephan A Grupp; Carl H June
Journal:  J Immunol       Date:  2015-08-01       Impact factor: 5.422

7.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Douglas C Palmer; Claudia Wrzesinski; Keith Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

8.  Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.

Authors:  Lena Al-Harthi; John Voris; Wenbo Du; David Wright; Marek Nowicki; Toni Frederick; Alan Landay; Andrea Kovacs
Journal:  J Infect Dis       Date:  2006-03-17       Impact factor: 5.226

Review 9.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.